MedTrace Logo

Reducing Fall Risk Post Hip Fracture in Mild Cognitive Impairment

NCT04748354 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-11-24

No results posted yet for this study

Summary

Hip fracture is recognized as one of the most serious consequences of osteoporosis, less than half regain pre-fracture independence. 95% of all hip fractures in older adults are due to falls. Thus, reducing fall risk while restoring function post-hip fracture is critical. Many with fall-related hip fractures have cognitive impairment; cognitive impairment increases the risk of falls. The purpose of this 6-month proof-of-concept randomized controlled trial (RCT) is to assess the efficacy of the home-based Otago Exercise Program (OEP) compared with usual care in reducing fall risk among older adults with mild cognitive impairment (MCI) and a fall-related hip fracture.

Conditions

Interventions

BEHAVIORAL

Otago Exercise Program

An individualized and home-based program of progressive strength and balance training exercises delivered by a physical therapist

OTHER

Usual Care

Clinical care provided by a geriatrician.

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Teresa Liu-Ambrose, PhD · University of British Columbia

  • Larry Dian, MD · University of British Columbia

  • Jennifer C Davis, PhD · University of British Columbia

  • Deborha Jehu, PhD · University of British Columbia

  • Pierre Guy, MD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-03
Primary Completion
2024-03-30
Completion
2024-05-09

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04748354 on ClinicalTrials.gov